Recursion Pharmaceuticals (RXRX) Stock Price

Financial Performance

Recursion Pharmaceuticals has shown an impressive performance in terms of revenue, gross profit, and operating income. The company's revenue has grown by 80.9% quarter-over-quarter and a massive 139.5% year-over-year to reach $26.1M. Similarly, the gross profit has seen a significant increase of 962.4% from the previous quarter and up by 211.2% year over year to hit $14M.

The operating income is negative at -$98.4M but it has improved by about 2.2% from the last quarter and up by around 9.9% YoY which indicates that the company is taking steps towards profitability.

The EBITDA ratio stands at -3.37 indicating that there are still challenges on their path to profitability.

Stock Price

The current stock price stands at $9.28 which is significantly higher than its 200-day moving average of $7.48 indicating bullish behavior in recent times.The RSI value currently stands at approximately mid-range (56), suggesting a balanced market sentiment with neither overbought nor oversold conditions prevailing.

Alternative Data Signals

In terms of alternative data signals, web traffic for Recursion Pharmaceuticals seems to be slightly down with an estimated monthly visitor count of approximately 63946 visitors per month which represents a decrease of -18.4%. However, the number of job openings remains steady at around 59 demonstrating potential growth plans.

Around an estimated majority (79%) of employees have reported having a positive business outlook for the firm which shows good internal morale and confidence in future prospects.

Social media followership also seems strong with Twitter followers up by 62.9% in the last 90 days and Facebook followers up by 12.3% in the same period.

Conclusion

In conclusion, despite some challenges, Recursion Pharmaceuticals seems to be on a growth trajectory with strong revenue and gross profit growth. The stock price is also performing well above its moving average although the RSI indicates a balanced market sentiment. Alternative data signals show strong social media presence and positive employee outlook but slightly decreasing web traffic. Overall, this analysis is moderately bullish on Recursion Pharmaceuticals' stock performance.

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $9.28, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.